Mild VI* | MSVI | Blindness | Any VI* | |||||
n/N | % (95% CI) | n/N | % (95% CI) | n/N | % (95% CI) | n/N | % (95% CI) | |
Men (years) | ||||||||
50–59 | 8/316 | 2.5 (0.8 to 4.3) | 3/339 | 0.9 (0 to 1.9) | 2/349 | 0.6 (0 to 1.4) | 22/316 | 7.0 (4.1 to 9.8) |
60–69 | 33/501 | 6.6 (4.4 to 8.8) | 26/570 | 4.6 (2.8 to 6.3) | 2/621 | 0.3 (0 to 0.8) | 76/501 | 15.2 (12 to 18.3) |
70–79 | 13/192 | 6.8 (3.2 to 10.4) | 27/267 | 10.1 (6.5 to 13.8) | 3/334 | 0.9 (0 to 1.9) | 43/192 | 22.4 (16.4 to 28.3) |
80+ | 1/26 | 3.9 (0 to 11.8) | 17/59 | 28.8 (16.9 to 40.7) | 4/88 | 4.6 (0.1 to 9) | 5/26 | 19.2 (3.0 to 35.5) |
Total | 55/1035 | 5.3 (3.9 to 6.7) | 73/1235 | 5.9 (4.6 to 7.2) | 11/1392 | 0.8 (0.3 to 1.3) | 146/1035 | 14.1 (12.0 to 16.2) |
Women (years) | ||||||||
50–59 | 31/502 | 6.2 (4.1 to 8.3) | 7/554 | 1.3 (0.3 to 2.2) | 4/574 | 0.7 (0 to 1.4) | 56/502 | 11.2 (8.4 to 13.9) |
60–69 | 39/413 | 9.4 (6.6 to 12.3) | 24/508 | 4.7 (2.9 to 6.6) | 1/566 | 0.2 (0 to 0.5) | 90/413 | 21.8 (17.8 to 25.8) |
70–79 | 18/146 | 12.3 (6.9 to 17.7) | 47/256 | 18.4 (13.6 to 23.1) | 4/342 | 1.2 (0 to 2.3) | 42/146 | 28.8 (21.3 to 36.2) |
80+ | 1/26 | 4.8 (0 to 11.8) | 24/65 | 36.9 (24.9 to 49.0) | 3/113 | 2.7 (0 to 5.7) | 6/21 | 28.6 (7.5 to 49.6) |
Total | 89/1082 | 8.2 (6.6 to 9.9) | 102/1383 | 7.4 (6 to 8.8) | 12/1595 | 0.8 (0.3 to 1.2) | 194/1082 | 17.9 (15.6 to 20.2) |
Full population (years) | ||||||||
50–59 | 39/818 | 4.8 (3.3 to 6.2) | 10/893 | 1.1 (0.4 to 1.8) | 6/923 | 0.7 (0.1 to 1.2) | 78/818 | 9.5 (7.5 to 11.6) |
60–69 | 72/914 | 7.9 (6.1 to 9.6) | 50/1078 | 4.6 (3.4 to 5.9) | 3/1187 | 0.3 (0 to 0.5) | 166/914 | 18.2 (15.7 to 20.7) |
70–79 | 31/338 | 9.2 (6.1 to 12.3) | 74/523 | 14.2 (11.2 to 17.1) | 7/676 | 1.0 (0.3 to 1.8) | 85/338 | 25.2 (20.5 to 29.8) |
80+ | 2/47 | 4.3 (0 to 10.2) | 41/124 | 33.1 (24.7 to 41.5) | 7/201 | 3.5 (0.9 to 6.0) | 11/47 | 23.4 (10.8 to 36.0) |
Total | 144/2117 | 6.8 (5.7 to 7.9) | 175/2618 | 6.7 (5.7 to 7.6) | 23/2987 | 0.8 (0.5 to 1.1) | 340/2117 | 16.1 (14.5 to 17.6) |
Standardised | 6.4 (5.3 to 7.5) | 6.3 (5.4 to 7.3) | 0.8 (0.4 to 1.1) | 15.6 (13.8 to 17.4) |
*Incidence was significantly higher in women than in men (p<0.05, Pearson χ2 test).
MSVI, moderate and serve visual impairment; VI, visual impairment.